Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus
- 21 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 19 (2), 297-302
- https://doi.org/10.1007/s10147-013-0564-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biology & Therapy, 2010
- Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnnals Of Oncology, 2009
- Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and AgeJNCI Journal of the National Cancer Institute, 2008
- Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusBritish Journal of Cancer, 2008
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- Epidermal growth factor receptor inhibition strategies in oncologyEndocrine-Related Cancer, 2004
- Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer PatientsJournal of Clinical Oncology, 2004
- Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibodyInternational Journal of Cancer, 2002
- INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation TherapyJournal of Clinical Oncology, 2002